Articles tagged with Tumor Growth
Researchers developed RegVelo, an AI framework that models cellular dynamics and gene regulation to predict cellular fate decisions. The model traces developmental trajectories and simulates regulatory interactions, providing insights into hidden drivers of development and potential therapeutic targets.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A research team at the University of Cologne discovered that the protein cFLIP can be used to override the defences of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. Targeting cFLIP could re-activate cell death in lymphoma cells and provide a new therapy option.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
Chemokines regulate immune cell infiltration and local immunity in tumors, and targeting their receptor axis has emerged as a promising therapeutic target in cancer immunotherapy. Chemokine-modulating strategies combining with other immunotherapies have demonstrated considerable synergistic potential.
Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
A new article in JMIR Publications showcases precision oncology's success, where individualized multi-drug regimens improve treatment responses and survival rates for patients with advanced cancers. The study found that closely matching drug therapies to tumor mutations leads to better outcomes, while also offering a safer profile.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A recent study found that women have a 21% lower risk of death compared to men, but a 12% higher risk of severe side effects from cancer treatment. The research, conducted in partnership with international collaborators, analyzed data from over 20,000 cancer patients and identified sex-based differences in survival and treatment toxicity.
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
New research reveals that tumor cells in supratentorial ependymomas cluster into distinct neighborhoods, each with a specific role, such as proliferating or invading. Understanding these cell subtypes could help predict treatment response and inform targeted therapies for this aggressive childhood brain cancer.
Severe COVID-19 and influenza infections can prime the lungs for cancer development, according to new research. Vaccination, however, largely prevents these changes, suggesting a reduced risk of lung cancer.
Researchers at the University of Gothenburg have identified a protein, ATF4, linked to increased metastasis and recurrence in lung cancer. The study reveals that older individuals' tumors are smaller and grow more slowly, yet more likely to have spread when detected.
A new clinical study aims to improve communication between patients and families about genetic risks of colorectal cancer. The trial will compare two methods of sharing genetic test results with close relatives, with the goal of learning which approach helps more family members get necessary genetic testing.
A new study shows that pancreatic cancer cells' ability to detect the extracellular matrix determines their growth rate and response to chemotherapy. The researchers found that cells detecting ECM have low autophagy levels and high growth rates, while those farther away from ECM have high autophagy levels and can survive chemotherapy.
A Mass General Brigham-led study found that integrating feedback and personalized palliative care can improve the quality of life for children with advanced cancer. The study showed significant improvements in symptoms and well-being for patients who received the intervention, highlighting the potential benefits of early palliative care.
Researchers found that certain gut bacteria can deplete amino acids, affecting tumor growth or activating immune cells. Tailoring diets and microbiome strategies may enhance anti-tumor activity and support personalized therapy.
A machine-learning-based approach has been developed to map real-time tumor metabolism in brain cancer patients, helping doctors discover effective treatment strategies. The digital twin uses patient data to calculate metabolic flux, predicting which treatments are likely to work for individual cases of glioma.
A new study published in CANCER found that men are more likely to have advanced disease and high myeloma load at diagnosis compared to women. Men were also less likely to have low bone mineral density and had different chromosomal abnormalities, which may contribute to the sex disparity in multiple myeloma risk.
Researchers identified specific microbial patterns associated with tumor location, genetic features, and patient outcomes. A new Microbial Risk Score (MRS) offers a practical way to translate complex microbiome data into prognostic insight.
A recent study published in Gut journal revealed that Streptococcus anginosus produces methionine metabolites, which significantly contribute to the development of gastric cancer. The research opens new paths for microbiota-targeted prevention strategies.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
Researchers discovered a novel mechanism behind small cell lung cancer's aggressiveness, involving the lack of caspase-8, leading to necroptosis and inflammation that fosters tumor progression. This pre-tumoral inflammation suppresses anti-cancer immune responses, promoting metastasis and relapse.
A recent review suggests that Clostridioides difficile infection may promote the development of gastrointestinal tumors, including colorectal cancer. The bacterium's toxins can cause damage to the epithelial cytoskeleton and induce inflammation, leading to chronic colitis and increased risk of CRC.
Researchers at UT Health San Antonio are developing APOBEC inhibitors to block tumor mutation rates and slow cancer's evolution. The goal is to strengthen current therapies and improve their long-term effectiveness.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
A specific protein, RASH3D19, activates the RAS signaling pathway involved in aggressive tumor growth and resistance to KRAS inhibitors. Blocking RASH3D19 improves outcomes in preclinical models, suggesting a potential therapeutic strategy.
A microRNA cocktail has been developed to weaken glioblastoma, a type of aggressive brain tumor. The formulation, comprising 11 different non-coding RNAs, slows the growth of cancer cells and enhances chemotherapeutic drug activity.
Researchers identified a targeted drug that blocks a specific genetic pathway to reverse tumor-driving cellular interactions, potentially restoring DNA function and benefiting patients with synovial sarcoma. The study's findings endorse a promising strategy to improve outcomes for this rare but deadly cancer.
Researchers at UC Riverside and City of Hope have developed a novel Pin1 degrading compound that suppresses pancreatic cancer peritoneal metastases. The treatment targets not only cancer cells but also tumor-supporting cells, potentially overcoming treatment resistance.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that aging accelerates pancreatic cancer progression, leading to faster tumor growth and metastasis. By understanding the impact of age on the tumor microenvironment, they developed a new approach to treating this disease in frail patients.
A study published in Molecular Cancer suggests that blocking the thyroid hormone receptor Beta, TRβ, can inhibit the growth of prostate cancer cells. This discovery may lead to a new way of treating certain types of aggressive prostate cancer.
A liquid biopsy test may enable early detection of various cancers, increasing stage I–III diagnoses by 10-30% and stage IV diagnoses by 45%. This could improve patient outcomes and reduce the economic impact of cancer. The study's findings suggest a game-changing approach to cancer control.
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Researchers discovered a mutation in the POT1 gene that prevents telomeres from repairing, leading to pulmonary fibrosis. This study highlights the importance of personalising treatments for diseases caused by dysfunctional telomeres.
Researchers reprogrammed the epigenetic code to affect tumour growth and survival in multiple myeloma. This study presents a comprehensive map of epigenetic alterations in multiple myeloma, highlighting site-specific increases in DNA and protein methylation that control gene activity.
Researchers found that lung cancer cells can form functional synapses with neurons, supporting their growth and survival. Disrupting glutamate signalling led to lower tumour burden and longer survival in experimental mice, highlighting promising therapeutic targets.
A new liquid biopsy tool, HPV-DeepSeek, can identify HPV-associated head and neck cancer in asymptomatic individuals up to 10 years before diagnosis. The test uses whole-genome sequencing to detect microscopic fragments of HPV DNA in the blood.
Researchers identified three distinct molecular subtypes of follicular lymphoma, offering insights into personalized treatment plans. The subtypes C1, C2, and C3 differ in their genetic profiles and tumor microenvironments, guiding the use of specific therapies.
Researchers envision AI-powered systems that identify patients at risk of mental health struggles, provide continuous psychological monitoring and tailor interventions. AI can also overcome barriers to mental health care by delivering support exactly where and when it's needed, including rural areas.
Researchers at Fox Chase Cancer Center have provided a detailed assessment of how fast breast cancers grow in patients and how surgical delays may affect breast cancer staging. The study found that upstaging rates associated with delays are relatively small and consistent with prior data.
Researchers at NTU Singapore and Oxford University have discovered a mechanism by which cells identify and repair highly toxic DNA damage, known as DPCs, that cause cancer, neurodegeneration, and premature ageing. The study reveals how SPRTN, a key repair enzyme, selectively targets DPC lesions, increasing its activity 67-fold.
A recent study identified 37 human-specific genes linked to brain development and cognitive abilities, which are hijacked by cancer to drive tumor growth. The researchers discovered nearly half of these genes become aberrantly activated in cancerous tissues, promoting tumor cell proliferation.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
A study of 62,839 people diagnosed with non-metastatic prostate cancer in Sweden found that those treated according to NCCN Guidelines were likely to survive their cancer for their remaining life-expectancy. Those with low- and intermediate-risk cancer were six times more likely to die of other causes than prostate cancer.
Researchers have identified a hidden molecular mechanism involving two proteins that allows tumors to resist treatment. A new gelatin-based nanoparticle has been developed to shut down both proteins simultaneously, showing promising results in early studies with mice.
A study by Karolinska Institutet found that an AI tool improved pathologists' assessments of tissue samples from skin cancer tumours, leading to more consistent results and better prognoses. The tool helped quantify tumor-infiltrating lymphocytes, a biomarker in several cancers, including malignant melanoma.
Scientists at Nagoya University discovered that dying cancer cells can trigger an inflammatory feedback loop that promotes tumor growth. When macrophages consume dying cancer cells, they produce cytokines that activate growth signals in remaining cancer cells.
The Dresden research team developed an autonomous AI agent for precision medicine that can process multimodal data and have reasoning capabilities. The AI agent reached correct clinical conclusions in 91% of cases and accurately cited relevant oncology guidelines in over 75% of its responses.
Researchers examined baseline characteristics of adolescent and young adult (AYA) cancer survivors seen in oncology primary care clinic, finding high rates of comorbidities and cardiovascular disease. They also studied the overexpression of IRAK4 protein in acute myeloid leukemia (AML) cells, with potential implications for treatment.
The University of Houston has launched a $3M Cancer Immunotherapy Biomarker Core to accelerate early diagnosis and treatment response in cancer. The core will offer comprehensive targeted proteomic cancer biomarker screens, enabling researchers to identify better biomarkers for cancer.
Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.
Researchers at the University of Chicago Medicine discovered a new phenomenon where high doses of radiation cause growth in existing metastatic tumors. The 'badscopal effect' is attributed to increased production of amphiregulin, which weakens the immune system and makes cancer cells more resistant.
Pennington Biomedical welcomes Dr. Adithya Hari, MD, with expertise in nuclear oncology and translational science, strengthening cancer research and patient-centered innovation in Louisiana. He will establish a research program focused on nuclear medicine and dedicate time to direct patient care through a clinical partnership.
Researchers have developed three-dimensional spheroid cultures that better replicate cell-cell interactions and nutrient gradients, leading to a greater understanding of tumour tissue behaviour and drug responses. The study highlights the importance of mimicking tumour architecture in testing cancer therapies.
A predictive model combining tumor marker readings with patients' genetic profiles enhances predictions for patient survival and surgery decision-making. The new tool accurately identifies candidates who would benefit from surgery, suggesting that current tumor marker evaluations are inadequate for these genetic profiles.